non-small cell lung cancer (NSCLC), Esophageal Cancer, Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation research hub

A Phase 2, Safety and Efficacy Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

This study looks at a new drug, PRT3789, with an existing cancer treatment, Pembrolizumab, for advanced solid tumours like lung cancer. It checks how safe and effective this combination is for people whose cancer has a specific change called a SMARCA4 mutation.